eTRANSAFE
Enhancing TRANslational SAFEty Assessment through Integrative Knowledge Management (eTRANSAFE)
- A five-year project funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) together with the pharmaceutical industry.
- Development of an integrated data infrastructure and innovative computational methods to improve translational safety assessment.
Insight
The eTRANSAFE project will develop an integrated data infrastructure and innovative computational methods and tools to drastically improve the feasibility and reliability of translational safety assessment during the drug development process. This infrastructure will be underpinned by the development of open standards and robust policies widely accepted by stakeholders, including regulatory agencies and international organisations.
eTRANSAFE is a five-year project which started on 1st September 2017, funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) together with the pharmaceutical industry.
Lhasa Limited’s key contributions to the eTRANSAFE project include:
- acting as the data honest broker for pre-clinical study data (project work packages 3&4) – the role which Lhasa Limited also fulfilled in the IMI eTOX project;
- developing a technically advanced data management system for pre-clinical study data which is based on the SEND standard (work package 4);
- contributing to the overall design of the software platform (work package 9);
- developing internationally accepted policies for data sharing (work package 2);
- contributing to project sustainability planning (work package 10).
The following figure is taken from: http://etransafe.eu/structure/
More Information
More information on the eTRANSAFE project consortium, their scientific objectives and the latest project news and public results can be found at http://etransafe.eu/.
Consortium members can make a data donation to eTRANSAFE via Lhasa Limited’s eTRANSAFE Data Sharing Submission form.
eTRANSAFE has received support from IMI2 Joint Undertaking under Grant Agreement No. 777365. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
